Professional Documents
Culture Documents
PROFILE
Director / Associate Director, Program / Project Manager, Senior/Principal Scien
tist
Molecular diagnostics, biomarkers, gene-expression analysis, high-throughput tec
hnologies, serum autoantibody profiling, early stage cancer drug development, le
adership
Action-oriented executive possessing wealth of experience in biotechnology and a
cademic settings. Very strong management and leadership skills with the ability
to build data and human systems to achieve organizational goals. Highly organiz
ed. Very strong communication skills, both written and verbal. Multi-lingual.
* Skilled in managing new technology development
* Experienced in project management, and building international R&D teams
* Highly knowledgeable about bioinformatics and data-mining for novel biomarkers
* Expert in troubleshooting puzzling experimental inconsistencies
* Successful at writing peer-review papers, winning grants, and conference prese
ntations
* Strong at translating experimental medicine into clinical context
* Capable of building websites, creating flash movies for on-line advertising an
d marketing campaigns
* Proficient with FDA requirements for in vitro diagnostic devices and CLSI stan
dards
EXPERIENCE
Protobios O, Estonia, EU 2009-Present
Molecular diagnostics R&D biotech start-up specializing in oncology and auto imm
une disease. 24 employees.
Director, Molecular Diagnostics & Biomarkers
Reports to the CEO and CSO. Responsible for the design and execution of the com
panys molecular diagnostics strategies. Summarized progress reports for executi
ve management. Drafted and executed quarterly plans. Executed timely planned act
ivities. Determined the clinical need for planned molecular diagnostics products
. Contributed to small business grant writing efforts. Managed a group of 7 res
earch scientists and built a strong R& D team spirit. Implemented standardized w
orkflow and quality controls for R&D diagnostics.
* Enhanced existing technology of diagnostic biomarker discovery and personalize
d medicine; Result: Designed and implemented an ultra-high throughput technology
platform
* Coordinated proof-of-principle experiments for Global Mimotype Mapping (GMM) t
echnology; Result: Provisional Patent Global Mimotope Mapping (GMM) to determine
the state of human and animal health related to the immune memory: artificial i
ntelligence in human health management.
* Delivered standardized workflow for diagnostic serum autoantibody discovery by
phage display; Result: novel diagnostic markers for type 1 diabetes.
* Currently writing a Grant for technology development; Result: Grant in process
of completion prior to submission to European Union Granting Agencies.
PUBLICATIONS
1. Heuze-Vourch N, Liu M, Dalwadi H, Baratelli F, Zhu L, Goodglick L, Pld M, Sha
rma S, Ramirez R, Shay J, Minna JD, Strieter RM, Dubinett SM. IL-20, an anti-ang
iogenic cytokine that inhibits COX-2 expression. Biochem & Biophys Res Comm 2005
; 333:470475
2. Pld M, Krysan K, Pld A, Dohadwala M, Heuze-Vourch N, Mao JT, Riedl KL, Sharma
S, M. Dubinett SM. Cyclooxygenase-2 (COX-2) Modulates The Insulin-like Growth F
actor (IGF)-axis in Non-SmallCell Lung Cancer (NSCLC). Cancer Res. 2004; 64:6549
-55
3. Krysan K, Dalwadi H, Sharma S, Pld M, Dubinett S. COX-2-dependent expression
of survivin is critical for apoptosis resistance in NSCLC. Cancer Res. 2004; 64:
6359-62
4. Riedl KL, Krysan K, Pld M, Dalwadi H, Heuze-Vourch N, Dohodwala M, Liu M, Cui
X, Figlin R, Sharma S, Dubinett SM. Update on Cyclooxygenase-2 in Lung Cancer.
Drug Resistance Updates 2004; 7:169-84. Review
5. Krysan K, Dohadwala M, Luo J, Lin Y, Zhu L, Heuze-Vourch N, Goodglick L, Merc
hant F, Seligson D, Pld M, Strieter R, Sharma S, Dubinett S. Cyclooxygenase-2-de
pendent expression of survivin in non-small cell lung cancer. Chest. 2004;125:14
0S
6. Pld M, Zhu LX, Sharma S, Burdick MD, Lin Y, Lee PP, Pold A, Luo J, Krysan K,
Dohadwala M, Mao JT, Batra RK, Strieter RM, Dubinett SM. Cyclooxygenase-2-depend
ent expression of angiogenic CXC chemokines ENA-78/CXC Ligand (CXCL) 5 and inter
leukin-8/CXCL8 in human non-small cell lung cancer. Cancer Res. 2004;64:1853-60
7. Krysan K, Merchant FH, Zhu L, Dohadwala M, Luo J, Lin Y, Heuze-Vourch N, Pld
M, Seligson D, Chia D, Goodglick L, Wang H, Strieter R, Sharma S, Dubinett S. CO
X-2-dependent stabilization of survivin in non-small cell lung cancer. FASEB J.
2004;18:206-8
8. Dubinett SM, Sharma S, Huang M, Dohadwala M, Pld M, Mao JT. Cyclooxygenase-2
in lung cancer. Prog Exp Tumor Res. 2003;37:138-62
9. Batra RK, Lin Y, Sharma S, Dohadwala M, Luo J, Pld M, Dubinett SM. Non-small
cell lung cancer-derived soluble mediators enhance apoptosis in activated T lymp
hocytes through an I kappa B kinase-dependent mechanism. Cancer Res. 2003;63:642
-6
10. Sharma S, Huang M, Dohadwala M, Pld M, Batra RK, Dubinett SM. Cyclooxygenas
e 2-dependent regulation of antitumor immunity in lung cancer. Methods Mol Med.
2003;75:723-36
11. Dohadwala M, Batra RK, Luo J, Lin Y, Krysan K, Pld M, Sharma S, Dubinett SM.
Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer c
ells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent
invasion. J Biol Chem. 2002;277:50828-33
12. Pld M, Dohadwala M, Luo J, Lin Y, Dubinett S. Microarray identifies cyclo-ox
ygenase-2-dependent modulation of insulin-like growth factor binding protein-3 i
n non-small cell lung cancer cells. Chest. 2002;121:29S
13. Dohadwala M, Luo J, Zhu L, Lin Y, Dougherty GJ, Sharma S, Huang M, Pld M, Ba
tra RK, Dubinett SM. Non-small cell lung cancer cyclooxygenase-2-dependent invas
ion is mediated by CD44. J Biol Chem. 2001;276:20809-12
14. Ma HJ, Sjak-Shie NN, Vescio RA, Kaminsky M, Mikail A, Pld M, Parker K, Beksa
c M, Belson D, Moss TJ, Wu CH, Zhou J, Zhang L, Chen G, Said JW, Berenson JR. Hu
man herpesvirus 8 open reading frame 26 and open reading frame 65 sequences from
multiple myeloma patients: a shared pattern not found in Kaposis sarcoma or pri
mary effusion lymphoma. Clin Cancer Res. 2000;6:4226-33
15. Pld M, Pold A, Ma HJ, Sjak-Shie NN, Vescio RA, Berenson JR. Cloning of the f
irst invertebrate MAGE paralogue: an epitope that activates T-cells in humans is
highly conserved in evolution. Dev Comp Immunol. 2000;24:719-31
16. Pld M, Zhou J, Chen GL, Hall JM, Vescio RA, Berenson JR. Identification of a
new, unorthodox member of the MAGE gene family. Genomics. 1999;59:161-7
17. Rettig MB, Ma HJ, Vescio RA, Pld M, Schiller G, Belson D, Savage A, Nishikub
o C, Wu C, Fraser J, Said JW, Berenson JR. Kaposis sarcoma-associated herpesviru
s infection of bone marrow dendritic cells from multiple myeloma patients. Scien
ce. 1997;276:1851-4